Clinical Trials in La Roche-sur-Yon, France
1 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 2
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NSCLC Stage IV
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Not Applicable
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Phase 3
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Breast Cancer
AstraZeneca100 enrolled40 locationsNCT07205822
Recruiting
Not Applicable
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast CancerLung CancerComorbidities and Coexisting Conditions
Institut Bergonié720 enrolled10 locationsNCT05720910
Recruiting
Phase 4
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
GFPC Investigation500 enrolled41 locationsNCT06646471
Recruiting
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancer
GFPC Investigation1,000 enrolled46 locationsNCT07243132
Recruiting
Phase 2
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Triple Negative Breast Neoplasms
UNICANCER220 enrolled20 locationsNCT05973864
Recruiting
Phase 2
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
NSCLC
Groupe Francais De Pneumo-Cancerologie45 enrolled27 locationsNCT06620835
Recruiting
Not Applicable
Program of Physical Activity, Nutrition and Supportive to Improve the Quality of Life of Breast Cancer Survivors
Breast CancerQuality of Life
Siel Bleu160 enrolled8 locationsNCT05658341
Recruiting
Phase 3
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Head and Neck CancerRenal Cell CarcinomaLung Cancer Metastatic
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Not Applicable
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
Limited Stage Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC600 enrolled41 locationsNCT04790253